肠道菌群可作为防治高血压的新靶点?

系统性高血压(HTN)仍然是主要的心血管疾病的发病风险及死亡原因;难治性HTN(RH)在高血压患者中的所占比例达到了15%-20%。
本文讨论了肠道菌群作为HTN治疗靶点的潜在可能。
首先介绍了HTN及RH患者的肠道菌群特征,以及肠道菌群及其代谢产物在HTN及RH的发病、发展中的调节作用;提出肠道菌群可能作为载体,在家庭成员之间传播HTN表型。
探讨了用益生菌及益生元作为抗高血压药物的可能。
最后列举了这一领域待解决的问题。
延伸阅读

Circulation Research [IF:15.862]

Gut Microbiota: Potential for a Unifying Hypothesis for Prevention and Treatment of Hypertension

肠道菌群:防治高血压的潜能

10.1161/CIRCRESAHA.117.310734

2017-05-25, Opinion

Abstract & Authors:展开

Abstract:收起
Despite major advances in pharmacological and device-based therapies, systemic hypertension (HTN) continues to be the major, modifiable risk factor for most cardiovascular disease and a leading cause of morbidity and mortality. Treatment resistant HTN (RH) is present in ≈15% to 20% of hypertensive patients, with few treatment options. These facts provide an opportunity to develop novel hypotheses to advance this field.

First Authors:
YanFei Qi

Correspondence Authors:
Carl J Pepine

All Authors:
YanFei Qi,Seungbum Kim,Elaine M Richards,Mohan K Raizada,Carl J Pepine